ACPT Inhibitors
ACPT Inhibitors encompass a diverse array of chemical compounds that, through the inhibition of specific kinases and signaling pathways, can decrease the functional activity of ACPT. Staurosporine, as a kinase inhibitor, can impede the phosphorylation of ACPT, which is pivotal for its activation. This inhibition can lead to a decrease in ACPT-mediated signaling. Wortmannin and LY294002, both PI3K inhibitors, obstruct a key signaling pathway that can be upstream of ACPT activation. Their action results in a reduction of ACPT's activity by hindering the signaling cascade that would normally result in ACPT activation. Rapamycin's inhibition of mTOR may also indirectly suppress ACPT activity by downregulating pathways that could otherwise enhance ACPT function.
Further, PD173074 and Gefitinib, which target FGFR and EGFR respectively, can decrease signals that may be involved in ACPT activation. While these inhibitors may not directly target ACPT, they impede upstream signaling which is necessary for ACPT's functional activity. PP2 and Dasatinib, which inhibit Src family kinases, may prevent phosphorylation of ACPT or proteins within its activation pathway, leading to reduced ACPT activity. SB203580 and SP600125, targeting p38 MAPK and JNK respectively, can diminish the activation of factors that might stimulate ACPT.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a kinase inhibitor that targets a wide range of protein kinases. It can inhibit ACPT by blocking the phosphorylation process on specific amino acids that are crucial for ACPT's activation and subsequent signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinases (PI3K). Given PI3K's role in cellular signaling, its inhibition can hinder downstream signals that lead to the activation of ACPT, thereby reducing ACPT's functional activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and inhibits mTOR, a central controller of cell growth. This inhibition can downregulate signals that may promote ACPT activity, thus indirectly leading to its decreased functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor which impairs the PI3K/Akt pathway. Since ACPT may rely on PI3K/Akt signaling for its activity, blocking this pathway can suppress ACPT activity. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 is an FGFR inhibitor. Although not directly inhibiting ACPT, it can block the FGFR pathway, which may crosstalk with pathways involving ACPT, leading to a decrease in ACPT's activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a Src family kinase inhibitor. Src kinases can phosphorylate various proteins, potentially including ACPT. By inhibiting Src, PP2 could reduce ACPT's phosphorylation and activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAPK, which is involved in inflammatory responses and stress. By inhibiting p38 MAPK, SB203580 can prevent the activation of factors that may stimulate ACPT, thus indirectly reducing its activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that blocks the MAPK/ERK pathway. Since this pathway can be upstream of ACPT activation, inhibiting MEK can result in diminished ACPT activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. JNK is involved in cellular stress and inflammatory responses. Inhibition of JNK can decrease the signaling related to ACPT activation, leading to reduced ACPT activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is an inhibitor of multiple tyrosine kinases, including Src family kinases. By inhibiting these kinases, Dasatinib can disrupt signaling pathways that may activate ACPT, thus reducing its activity. | ||||||